peptide agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Modafinil is an eugeroic medication, which means that it promotes wakefulness and alertness. Modafinil is sold under the brand name Provigil among others. Modafinil is used to treat excessive daytime sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive. Despite being a CNS stimulant, the addiction and dependence liabilities of modafinil are considered very low. Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties. The similarities in effects with caffeine are not clearly established. Unlike other stimulants, modafinil does not induce a subjective feeling of pleasure or reward, which is commonly associated with euphoria, an intense feeling of well-being. Euphoria is a potential indicator of drug abuse, which is the compulsive and excessive use of a substance despite adverse consequences. In clinical trials, modafinil has shown no evidence of abuse potential, that is why modafinil is considered to have a low risk of addiction and dependence, however, caution is advised.
==== Surface gene variants among hepatitis B virus carriers ==== DNA sequences of HBsAg were obtained from 180 patients, in which 51 were chronic HBV carrier and 129 newly diagnosed patients, and compared with consensus sequences built with 168 HBV sequences imported from GenBank. Literature review and BLOSUM scores were used to define potentially altered antigenicity.
=== KwaZulu Bantustan === KwaZulu was a bantustan in South Africa, intended by the apartheid government as a semi-independent homeland for the Zulu people. The capital was moved from Nongoma to Ulundi in 1980. It was led until its abolition in 1994 by Chief Mangosuthu Buthelezi of the Zulu royal family and head of the Inkatha Freedom Party (IFP). It was merged with the surrounding South African province of Natal to form the new province of KwaZulu-Natal. The name KwaZulu translates roughly as Place of Zulus, or more formally Zululand.
Sources: en.wikipedia.org
==== 16th century ==== The first records relating to the Cossack villages: the "stanitsas", date back to 1549. In the year 1552 Don Cossacks under the command of Ataman Susar Fedorov joined the Army of Ivan the Terrible during the Siege of Kazan in 1552. On 2 June 1556 the Cossack regiment of Ataman Lyapun Filimonov, together with the Army of Moscovits comprising strelets, conquered and annexed the Astrakhan Khanate. During the reign of Ivan the Terrible (Ivan IV), the ataman Yermak Timofeyevich went on an expedition to conquer Siberia. After defeating Khan Kuchum in the fall of 1582 and occupying Isker, the capital of the Siberian Khanate, Yermak sent a force of Cossacks down the Irtysh in the winter of 1583. The detachment, led by Bogdan Bryazga (according to other sources, the Cossack chieftain Nikita Pan) passed through the lands of the Konda-Pelym Voguls and reached the walls of the town of Samarovo. Surprised by the Cossack attack, the Ostyaks surrendered. In the autumn of 1585, shortly after Yermak's death, Cossacks led by voevoda (army commander) Ivan Mansurov founded the first Russian fortified town in Siberia, Obskoy, at the mouth of the Irtysh river on the right bank of the Ob river. The Mansi and Khanty lands thus became part of the Russian state, finally secured by the founding of the cities of Pelym and Berezov in 1592 and Surgut in 1594. As a result of Yermak's expedition, Russia was able to annex Siberia.
Leghemoglobin is a molecular similar in structure to myoglobin that is currently being used in artificial meat products, such as the Impossible Burger, to simulate both the color and taste of meat. Similar in function to hemoglobin, leghemoglobin contains trace amounts of iron, but it is primarily found in plant roots.
== History == In 2006, Rich Reiff and George Fox purchased several publications from Reed Business Information's New Product Division, formerly known as Gordon Publications, with the backing of private equity provided by Catalyst Investors. Also in 2006, the company launched the FindGuru business-to-business-focused search engine as a revised and rebranded ReedLink tool originally available from Reed Business Information. In 2011, ABM acquired Continuity Insights and Vicon Publishing. Vicon Publishing was renamed by ABM to Vicon Business Media as a subsidiary operated out of New Hampshire. In 2013 ABM acquired eMedia Vitals. In 2014, the firm was sold by Catalyst to Owners Resource Group (ORG), a private equity firm based in Austin, Texas, for undisclosed terms. This acquisition was ORG's first foray in the media business. In March 2014, co-founder Richard Reiff left the firm, leaving the CEO position vacant, though there is an indication that Jim Lonergan was brought in as CEO by the new owner. In 2018, Lonergan was replaced by Bruce Cummings and the company rebranded, changing its name to Advantage Business Marketing. On June 11, 2019, Cummings told all employees that the company was filing for bankruptcy and immediately closing. Staff had until the end of the day to vacate the premises. No severance package was given to employees, customers lost much of what they'd purchased, and many vendors were never paid.
Sources: en.wikipedia.org
== Description == Helianthus tuberosus is a herbaceous perennial plant growing to 1.5–3 m (4 ft 11 in – 9 ft 10 in) tall with opposite leaves on the lower part of the stem but alternate towards the top. The leaves have a rough, hairy texture. Larger leaves on the lower stem are broad ovoid-acute and can be up to 30 cm (12 in) long. Leaves higher on the stem are smaller and narrower. The flowers are yellow and produced in capitate flowerheads, which are 5–10 cm (2–4 in) in diameter, with 10–20 ray florets and 60 or more small disc florets. The flowers are briefly fragrant, giving off a light, vanilla-chocolate scent. The tubers are often elongated and uneven, typically 7.5–10 cm (3–3+7⁄8 in) long and 3–5 cm (1–2 in) thick, and vaguely resembling a ginger root in appearance, with a crisp and crunchy texture when raw. They vary in color from pale brown to white, red, or purple.
== Reception == Kevin Knox, who was in charge of doughnuts food quality at Starbucks from 1987 to 1993, recalled on his blog in 2010 how George Howell, coffee veteran and founder of the Cup of Excellence, had been appalled at the dark roasted beans that Starbucks was selling in 1990. Talking to The New York Times in 2008, Howell stated his opinion that the dark roast used by Starbucks does not deepen the flavor of coffee, but instead can destroy purported nuances of flavor. The March 2007 issue of Consumer Reports compared American fast-food chain coffees and ranked Starbucks behind McDonald's Premium Roast in the middle of a coffee war. The magazine called Starbucks coffee "strong, but burnt and bitter enough to make your eyes water instead of open". As reported by Time in 2010, third wave coffee proponents generally criticize Starbucks for over-roasting beans. As a result, Starbucks retrained its baristas and changed its roasting methods in 2010 to "standardize quality over quantity". The Atlantic reported that this push for higher-quality coffee slowed down orders but stated that "[they] move their product pretty quickly, and with surprising accuracy". Forbes corroborated this trade off between efficiency and quality at Starbucks. In 2018, Business Insider conducted a test of Starbucks coffee judged by 100 coffee experts. It concluded that although staples of the menu were "too sugary", coffee quality materially improved with particularly strong showings in the firm's iced coffee and nitro cold brew coffee offerings.
=== Chemical glycosylation of the IgG Fc fragment === Nature has perfected glycosylation of proteins through a complex interaction of enzymes and carbohydrates over thousands of years. However, chemical glycosylation is still an obstacle due to the difficult synthesis of glycan in general. The synthesis of carbohydrate derivatives can be slow and tedious. Nonetheless, the interest in technologies to structurally mimic protein glycosylation is an appealing application as some protein functions solely depend on the pattern of the attached glycan. The Fc fragment of the IgG antibody, for example, is a homodimer with a highly conserved N-glycosylation site. The attached sugar moieties modulate the binding to specific immunoreceptors, thereby modifying the whole antibody function. Smith et al. demonstrate the application of the aldehyde tag as a chemical conjugation site for glycans. The aldehyde tag sequence was incooperated into the Fc construct and introduced into CHO (Chinese hamster ovary) cells. As controls, gene constructs were used in which the cysteine residue was mutated to an alanine. After expression, the Fc proteins were purified using a protein A/G agarose column. The conversion in CHO cells of cystein to formylglycine was examined using aminooxy AlexaFluor 488 and subsequent SDS-PAGE. However, fluorescence scanning displayed no fluorescence labeling, i.e. no formylglycine formation by endogenous FGE in CHO cells.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。